A 24-week clinical trial, involving randomized allocation into two groups. The objective is to assess the safety, tolerability, and efficacy of two doses of suprachoroidal triamcinolone acetonide suspension (Triesence®) delivered with the Oxulumis® microcatheterization device in subjects with previously treated Diabetic Macular Edema.

Approximately 20 eligible Diabetic Macular Edema subjects will undergo randomization with equal allocation between two dose levels of triamcinolone acetonide (2.4mg or 4.0mg) following a screening phase.

Starting at week four, subjects will be evaluated for potential follow-up treatment. The post-treatment follow-up period extends up to 24 weeks.